Literature DB >> 988654

[On the effect of mebendazole on metacestodes of Mesocestoides corti and Echinococcus multilocularis (author's transl)].

J Eckert, J Pohlenz.   

Abstract

Mebendazole (5-benzoyl-2-methoxycarbonylaminobenzimidazole) was highly effective against tetrathydridia of Mesocestoides corti in the peritoneal cavity, liver and in the subcutis of mice when administered orally in the food (450 or 465 ppm) from days 7 or 40/50 post infectionem (p.i.) for 10 or 20 days in total doses of approximately 660-1660 mg/kg body weight (b.w.). All tetrathyridia were killed when treatment began at day 7 p.i., and only some survived when medication was started on days 40/50 p.i. A treatment of 5 days was only partially effective. In experiments with Echinococcus multilocularis laboratory animals were intraperitoneally infected with metacestode tissue transplants. Beginning on days 4-7 p.i. or on day 40 p.i. the animals were treated for 5, 10 or 20/21 days with mebendazole medicated food. In mice a treatment for 10 or 20/21 days with total mebendazole doses of approximately 660-2180 mg/kg b.w. caused an average reduction on metacestode weight of 61-89%. An average reduction between 58 and 84% was achieved in Meriones after a treatment for 20/21 days with total doses of approximately 650/530 mg/kg b.w. However, histological examinations and transplantation experiments revealed that in most of the treated animals metacestode tissue survived and retained its capability for budding. On the other hand, indications for a partial destruction of the parasite tissue were found in some of the treated animals. The oral mebendazole treatment was well tolerated. After intraperitoneal injection of 3 X 150 mg/kg b.w. mebendazole - as applied by Campbell et al. (1975) - all of 36 mice or Meriones died.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 988654

Source DB:  PubMed          Journal:  Tropenmed Parasitol        ISSN: 0303-4208


  19 in total

1.  Serological diagnosis of echinococcosis: the diagnostic potential of native antigens.

Authors:  A Schweiger; F Grimm; I Tanner; B Müllhaupt; K Bertogg; N Müller; P Deplazes
Journal:  Infection       Date:  2011-11-11       Impact factor: 3.553

2.  Echinococcus multilocularis: antigenic variance between different parasite isolates.

Authors:  B Gottstein
Journal:  Parasitol Res       Date:  1991       Impact factor: 2.289

3.  Chemotherapy of experimental Echinococcus multilocularis in jirds.

Authors:  O Vanparijs
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

4.  In vitro activities of benzimidazoles against Echinococcus multilocularis metacestodes.

Authors:  H Jura; A Bader; M Frosch
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  The effect of lentinan on the resistance of mice to Mesocestoides corti.

Authors:  T R White; R C Thompson; W J Penhale; G Chihara
Journal:  Parasitol Res       Date:  1988       Impact factor: 2.289

6.  The production of eggs by Echinococcus multilocularis in the laboratory following in vivo and in vitro development.

Authors:  R C Thompson; J Eckert
Journal:  Z Parasitenkd       Date:  1982

Review 7.  Chemotherapy for larval echinococcosis in animals and humans: report of a workshop.

Authors:  P M Schantz; H Van den Bossche; J Eckert
Journal:  Z Parasitenkd       Date:  1982

8.  Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man.

Authors:  F Witassek; B Burkhardt; J Eckert; J Bircher
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Cryopreservation of Echinococcus multilocularis metacestodes and subsequent proliferation in rodents (Meriones).

Authors:  J Eckert; T Ramp
Journal:  Z Parasitenkd       Date:  1985

10.  Echinococcus multilocularis: immunological study on the "Em2-positive" laminated layer during in vitro and in vivo post-oncospheral and larval development.

Authors:  B Gottstein; P Deplazes; M Aubert
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.